inhibitor p121 (CEM Corporation)
90
Structured Review
CEM Corporation
inhibitor p121
Inhibitor P121, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/inhibitor+p121/inhibitor+p121/pm24552657-151-14-19
Average 90 stars, based on 1 article reviews
Inhibitor P121, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/inhibitor+p121/inhibitor+p121/pm24552657-151-14-19
Average 90 stars, based on 1 article reviews
inhibitor p121 - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Blocking Assay:Article Title: Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924. Article Snippet: PR-924 is a novel prototypic immunoproteasome inhibitor bearing markedly enhanced specificity for the b5i immunoproteasome subunit, compared to the classical proteasome inhibitor bortezomib.. Here, we assessed the growth inhibitory potential of PR-924 in three human hematologic malignancy cell lines (CCRF-CEM, THP1, and 8226) and their bortezomib-resistant sublines.. Parental cells displayed equal sensitivity to PR-924 (IC50: 1.5–2.8 mM), whereas their bortezomib-resistant tumor lines displayed a 10– 12 fold cross-resistance to PR-924. Activity Assay:Article Title: Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924. Article Snippet: PR-924 is a novel prototypic immunoproteasome inhibitor bearing markedly enhanced specificity for the b5i immunoproteasome subunit, compared to the classical proteasome inhibitor bortezomib.. Here, we assessed the growth inhibitory potential of PR-924 in three human hematologic malignancy cell lines (CCRF-CEM, THP1, and 8226) and their bortezomib-resistant sublines.. Parental cells displayed equal sensitivity to PR-924 (IC50: 1.5–2.8 mM), whereas their bortezomib-resistant tumor lines displayed a 10– 12 fold cross-resistance to PR-924. |